Brazil suspends dengue vaccine after two suspected deaths

Brazil has temporarily halted the use of its dengue vaccine, Qdenga, after two individuals reportedly died under suspicious circumstances following inoculation. The move by the Brazilian health authorities introduces a significant pause in the country's efforts to combat the mosquito-borne disease.

Qdenga, developed by Takeda Pharmaceutical Company, is the sole dengue vaccine available globally, apart from another option, TAK-003. The suspension casts a shadow over the accessibility and safety of dengue prevention methods, particularly in regions heavily affected by the virus.

The situation is further complicated by the fact that the alternative vaccine, TAK-003, requires a specific two-dose administration schedule, with the second dose given three months after the first. This suspension in Brazil leaves limited options for widespread vaccination campaigns against dengue, a disease that poses a significant public health challenge in many tropical and subtropical areas.